T-Cell Subsets in Experimental Allergic Encephalomyelitis: Interactions between the Immune and Neuroendocrine Systems in the Regulation of Their Activity

Author(s):  
Don Mason
1975 ◽  
Vol 141 (1) ◽  
pp. 72-81 ◽  
Author(s):  
D E McFarlin ◽  
S C Hsu ◽  
S B Slemenda ◽  
F C Chou ◽  
R F Kibler

After challenge with guiena pig basic protein (GPBP) Lewis (Le) rats, which are homozygous for the immune response experimental allergic encephalomyelitis (Ir-EAE) gene, developed positive delayed skin tests against GPBP and the 43 residue encephalitogenic fragment (EF); in addition, Le rat lymph node cells (LNC) were stimulated and produced migration inhibitory factor (MIF) when incubated in vitro with these antigens. In contrast Brown Norway (BN) rats, which lack the Ir-EAE gene, did not develop delayed skin tests to EF and their LNC were not stimulated and did not produce MIF when incubated in vitro with EF. These observations indicate that the Ir-EAE gene controls a T-cell response against the EF. Le rats produced measurable anti-BP antibody by radioimmunoassay after primary challenge. Although no antibody was detectable in BN rats by radioimmunoassay, radioimmunoelectrophoresis indicated that a small amount of antibody was formed after primary immunization. After boosting intraperitoneally, both strains of rat exhibited a rise in anti-BP antibody; which was greater in Le rats. In both strains of rat the anti-BP antibody reacted with a portion of the molecule other than the EF. Since EF primarily evokes a T cell response, it is suggested that the EF portion of the BP molecule may contain a helper determinant in antibody production.


Genome ◽  
1989 ◽  
Vol 31 (2) ◽  
pp. 656-661 ◽  
Author(s):  
Hans Acha-Orbea ◽  
L. Steinman ◽  
H. O. McDevitt

The optimal form of treatment for an autoimmune disease should be highly specific, have few side effects, and allow treatment of clinically apparent disease. One target that could fulfill these requirements is the T cell receptor. To answer the question whether treatment of autoimmune disesase is possible with anti-T cell receptor antibodies, the heterogeneity of T cell receptor elements utilized in the T cell mediated autoimmune disease experimental allergic encephalomyelitis was analyzed. The limited heterogeneity of these elements allowed prevention and treatment of clinical autoimmune disease with anti-T cell receptor monoclonal antibodies. These results and their potential value for other autoimmune diseases are discussed.Key words: T cell receptor, autoimmune disease, monoclonal antibody therapy, experimental allergic encephalomyelitis.


1991 ◽  
Vol 137 (2) ◽  
pp. 367-378 ◽  
Author(s):  
Jérôme Rossert ◽  
Lucette Pelletier ◽  
Régine Pasquier ◽  
Henri Villarroya ◽  
Rafael Oriol ◽  
...  

1991 ◽  
Vol 31 (2) ◽  
pp. 165-177 ◽  
Author(s):  
Maha Ibrahim Mustafa ◽  
Per Diener ◽  
Höjeberg Bo ◽  
Peter Van der Meide ◽  
Tomas Olsson

Sign in / Sign up

Export Citation Format

Share Document